Advanced Enzyme Technologies Limited
Advanced Enzyme Technologies Limited (ADVENZYMES.BO) Stock Competitors & Peer Comparison
See (ADVENZYMES.BO) competitors and their performances in Stock Market.
Peer Comparison Table: Chemicals - Specialty Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ADVENZYMES.BO | ₹376.50 | -2.95% | 42B | 24.94 | ₹15.05 | +1.39% |
| ASIANPAINT.NS | ₹2,657.80 | +2.27% | 2.5T | 65.96 | ₹40.02 | +0.95% |
| ASIANPAINT.BO | ₹2,656.40 | +2.23% | 2.5T | 65.61 | ₹40.22 | +0.95% |
| SOLARINDS.NS | ₹18,377.00 | -0.08% | 1.6T | 97.61 | ₹185.76 | +0.06% |
| SOLARINDS.BO | ₹18,378.50 | -0.04% | 1.6T | 97.62 | ₹185.69 | +0.06% |
| PIDILITIND.BO | ₹1,476.85 | +0.39% | 1.5T | 65.84 | ₹22.48 | +1.01% |
| PIDILITIND.NS | ₹1,477.20 | +0.30% | 1.5T | 61.55 | ₹24.02 | +1.01% |
| SRF.NS | ₹2,711.00 | +3.46% | 782.4B | 42.61 | ₹61.94 | +0.34% |
| SRF.BO | ₹2,711.75 | +3.51% | 781.7B | 42.66 | ₹61.83 | +0.34% |
| LINDEINDIA.NS | ₹7,255.00 | -0.30% | 615.9B | 104.76 | ₹68.94 | +0.17% |
Stock Comparison
ADVENZYMES.BO vs ASIANPAINT.NS Comparison May 2026
ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADVENZYMES.BO stands at 42B. In comparison, ASIANPAINT.NS has a market cap of 2.5T. Regarding current trading prices, ADVENZYMES.BO is priced at ₹376.50, while ASIANPAINT.NS trades at ₹2,657.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADVENZYMES.BO currently has a P/E ratio of 24.94, whereas ASIANPAINT.NS's P/E ratio is 65.96. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to ASIANPAINT.NS's ROE of +0.20%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to ASIANPAINT.NS. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check ASIANPAINT.NS's competition here
ADVENZYMES.BO vs ASIANPAINT.BO Comparison May 2026
ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADVENZYMES.BO stands at 42B. In comparison, ASIANPAINT.BO has a market cap of 2.5T. Regarding current trading prices, ADVENZYMES.BO is priced at ₹376.50, while ASIANPAINT.BO trades at ₹2,656.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADVENZYMES.BO currently has a P/E ratio of 24.94, whereas ASIANPAINT.BO's P/E ratio is 65.61. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to ASIANPAINT.BO's ROE of +0.20%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to ASIANPAINT.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check ASIANPAINT.BO's competition here
ADVENZYMES.BO vs SOLARINDS.NS Comparison May 2026
ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADVENZYMES.BO stands at 42B. In comparison, SOLARINDS.NS has a market cap of 1.6T. Regarding current trading prices, ADVENZYMES.BO is priced at ₹376.50, while SOLARINDS.NS trades at ₹18,377.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADVENZYMES.BO currently has a P/E ratio of 24.94, whereas SOLARINDS.NS's P/E ratio is 97.61. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to SOLARINDS.NS's ROE of +0.33%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to SOLARINDS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check SOLARINDS.NS's competition here
ADVENZYMES.BO vs SOLARINDS.BO Comparison May 2026
ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADVENZYMES.BO stands at 42B. In comparison, SOLARINDS.BO has a market cap of 1.6T. Regarding current trading prices, ADVENZYMES.BO is priced at ₹376.50, while SOLARINDS.BO trades at ₹18,378.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADVENZYMES.BO currently has a P/E ratio of 24.94, whereas SOLARINDS.BO's P/E ratio is 97.62. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to SOLARINDS.BO's ROE of +0.33%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to SOLARINDS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check SOLARINDS.BO's competition here
ADVENZYMES.BO vs PIDILITIND.BO Comparison May 2026
ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADVENZYMES.BO stands at 42B. In comparison, PIDILITIND.BO has a market cap of 1.5T. Regarding current trading prices, ADVENZYMES.BO is priced at ₹376.50, while PIDILITIND.BO trades at ₹1,476.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADVENZYMES.BO currently has a P/E ratio of 24.94, whereas PIDILITIND.BO's P/E ratio is 65.84. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to PIDILITIND.BO's ROE of +0.24%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to PIDILITIND.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check PIDILITIND.BO's competition here
ADVENZYMES.BO vs PIDILITIND.NS Comparison May 2026
ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADVENZYMES.BO stands at 42B. In comparison, PIDILITIND.NS has a market cap of 1.5T. Regarding current trading prices, ADVENZYMES.BO is priced at ₹376.50, while PIDILITIND.NS trades at ₹1,477.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADVENZYMES.BO currently has a P/E ratio of 24.94, whereas PIDILITIND.NS's P/E ratio is 61.55. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to PIDILITIND.NS's ROE of +0.24%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to PIDILITIND.NS. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check PIDILITIND.NS's competition here
ADVENZYMES.BO vs SRF.NS Comparison May 2026
ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADVENZYMES.BO stands at 42B. In comparison, SRF.NS has a market cap of 782.4B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹376.50, while SRF.NS trades at ₹2,711.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADVENZYMES.BO currently has a P/E ratio of 24.94, whereas SRF.NS's P/E ratio is 42.61. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to SRF.NS's ROE of +0.14%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to SRF.NS. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check SRF.NS's competition here
ADVENZYMES.BO vs SRF.BO Comparison May 2026
ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADVENZYMES.BO stands at 42B. In comparison, SRF.BO has a market cap of 781.7B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹376.50, while SRF.BO trades at ₹2,711.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADVENZYMES.BO currently has a P/E ratio of 24.94, whereas SRF.BO's P/E ratio is 42.66. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to SRF.BO's ROE of +0.14%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to SRF.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check SRF.BO's competition here
ADVENZYMES.BO vs LINDEINDIA.NS Comparison May 2026
ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADVENZYMES.BO stands at 42B. In comparison, LINDEINDIA.NS has a market cap of 615.9B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹376.50, while LINDEINDIA.NS trades at ₹7,255.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADVENZYMES.BO currently has a P/E ratio of 24.94, whereas LINDEINDIA.NS's P/E ratio is 104.76. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to LINDEINDIA.NS's ROE of +0.16%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to LINDEINDIA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check LINDEINDIA.NS's competition here
ADVENZYMES.BO vs LINDEINDIA.BO Comparison May 2026
ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADVENZYMES.BO stands at 42B. In comparison, LINDEINDIA.BO has a market cap of 613.7B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹376.50, while LINDEINDIA.BO trades at ₹7,258.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADVENZYMES.BO currently has a P/E ratio of 24.94, whereas LINDEINDIA.BO's P/E ratio is 104.26. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to LINDEINDIA.BO's ROE of +0.16%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to LINDEINDIA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check LINDEINDIA.BO's competition here
ADVENZYMES.BO vs BERGEPAINT.NS Comparison May 2026
ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADVENZYMES.BO stands at 42B. In comparison, BERGEPAINT.NS has a market cap of 584.3B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹376.50, while BERGEPAINT.NS trades at ₹504.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADVENZYMES.BO currently has a P/E ratio of 24.94, whereas BERGEPAINT.NS's P/E ratio is 51.88. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to BERGEPAINT.NS's ROE of +0.18%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to BERGEPAINT.NS. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check BERGEPAINT.NS's competition here
ADVENZYMES.BO vs BERGEPAINT.BO Comparison May 2026
ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADVENZYMES.BO stands at 42B. In comparison, BERGEPAINT.BO has a market cap of 584B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹376.50, while BERGEPAINT.BO trades at ₹506.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADVENZYMES.BO currently has a P/E ratio of 24.94, whereas BERGEPAINT.BO's P/E ratio is 54.03. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to BERGEPAINT.BO's ROE of +0.18%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to BERGEPAINT.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check BERGEPAINT.BO's competition here
ADVENZYMES.BO vs FLUOROCHEM.NS Comparison May 2026
ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADVENZYMES.BO stands at 42B. In comparison, FLUOROCHEM.NS has a market cap of 421.2B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹376.50, while FLUOROCHEM.NS trades at ₹3,832.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADVENZYMES.BO currently has a P/E ratio of 24.94, whereas FLUOROCHEM.NS's P/E ratio is 64.21. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to FLUOROCHEM.NS's ROE of +0.09%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to FLUOROCHEM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check FLUOROCHEM.NS's competition here
ADVENZYMES.BO vs FLUOROCHEM.BO Comparison May 2026
ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADVENZYMES.BO stands at 42B. In comparison, FLUOROCHEM.BO has a market cap of 421.1B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹376.50, while FLUOROCHEM.BO trades at ₹3,830.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADVENZYMES.BO currently has a P/E ratio of 24.94, whereas FLUOROCHEM.BO's P/E ratio is 64.13. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to FLUOROCHEM.BO's ROE of +0.09%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to FLUOROCHEM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check FLUOROCHEM.BO's competition here
ADVENZYMES.BO vs HSCL.NS Comparison May 2026
ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADVENZYMES.BO stands at 42B. In comparison, HSCL.NS has a market cap of 296.2B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹376.50, while HSCL.NS trades at ₹593.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADVENZYMES.BO currently has a P/E ratio of 24.94, whereas HSCL.NS's P/E ratio is 39.14. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to HSCL.NS's ROE of +0.18%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to HSCL.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check HSCL.NS's competition here
ADVENZYMES.BO vs HSCL.BO Comparison May 2026
ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADVENZYMES.BO stands at 42B. In comparison, HSCL.BO has a market cap of 296.2B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹376.50, while HSCL.BO trades at ₹592.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADVENZYMES.BO currently has a P/E ratio of 24.94, whereas HSCL.BO's P/E ratio is 39.06. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to HSCL.BO's ROE of +0.18%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to HSCL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check HSCL.BO's competition here
ADVENZYMES.BO vs ACUTAAS.NS Comparison May 2026
ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADVENZYMES.BO stands at 42B. In comparison, ACUTAAS.NS has a market cap of 241.6B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹376.50, while ACUTAAS.NS trades at ₹2,923.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADVENZYMES.BO currently has a P/E ratio of 24.94, whereas ACUTAAS.NS's P/E ratio is 84.49. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to ACUTAAS.NS's ROE of +0.24%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to ACUTAAS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check ACUTAAS.NS's competition here
ADVENZYMES.BO vs ACUTAAS.BO Comparison May 2026
ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADVENZYMES.BO stands at 42B. In comparison, ACUTAAS.BO has a market cap of 241.4B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹376.50, while ACUTAAS.BO trades at ₹2,920.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADVENZYMES.BO currently has a P/E ratio of 24.94, whereas ACUTAAS.BO's P/E ratio is 84.03. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to ACUTAAS.BO's ROE of +0.12%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to ACUTAAS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check ACUTAAS.BO's competition here
ADVENZYMES.BO vs ATUL.NS Comparison May 2026
ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADVENZYMES.BO stands at 42B. In comparison, ATUL.NS has a market cap of 207.1B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹376.50, while ATUL.NS trades at ₹7,039.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADVENZYMES.BO currently has a P/E ratio of 24.94, whereas ATUL.NS's P/E ratio is 30.58. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to ATUL.NS's ROE of +0.12%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to ATUL.NS. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check ATUL.NS's competition here
ADVENZYMES.BO vs ATUL.BO Comparison May 2026
ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADVENZYMES.BO stands at 42B. In comparison, ATUL.BO has a market cap of 206.8B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹376.50, while ATUL.BO trades at ₹7,020.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADVENZYMES.BO currently has a P/E ratio of 24.94, whereas ATUL.BO's P/E ratio is 34.81. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to ATUL.BO's ROE of +0.12%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to ATUL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check ATUL.BO's competition here
ADVENZYMES.BO vs KANSAINER.NS Comparison May 2026
ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADVENZYMES.BO stands at 42B. In comparison, KANSAINER.NS has a market cap of 176.2B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹376.50, while KANSAINER.NS trades at ₹218.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADVENZYMES.BO currently has a P/E ratio of 24.94, whereas KANSAINER.NS's P/E ratio is 29.94. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to KANSAINER.NS's ROE of +0.09%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to KANSAINER.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check KANSAINER.NS's competition here
ADVENZYMES.BO vs KANSAINER.BO Comparison May 2026
ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADVENZYMES.BO stands at 42B. In comparison, KANSAINER.BO has a market cap of 176.2B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹376.50, while KANSAINER.BO trades at ₹218.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADVENZYMES.BO currently has a P/E ratio of 24.94, whereas KANSAINER.BO's P/E ratio is 30.10. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to KANSAINER.BO's ROE of +0.09%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to KANSAINER.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check KANSAINER.BO's competition here
ADVENZYMES.BO vs DCMSHRIRAM.BO Comparison May 2026
ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADVENZYMES.BO stands at 42B. In comparison, DCMSHRIRAM.BO has a market cap of 173.4B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹376.50, while DCMSHRIRAM.BO trades at ₹1,090.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADVENZYMES.BO currently has a P/E ratio of 24.94, whereas DCMSHRIRAM.BO's P/E ratio is 20.33. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to DCMSHRIRAM.BO's ROE of +0.12%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to DCMSHRIRAM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check DCMSHRIRAM.BO's competition here
ADVENZYMES.BO vs DCMSHRIRAM.NS Comparison May 2026
ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADVENZYMES.BO stands at 42B. In comparison, DCMSHRIRAM.NS has a market cap of 173.4B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹376.50, while DCMSHRIRAM.NS trades at ₹1,090.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADVENZYMES.BO currently has a P/E ratio of 24.94, whereas DCMSHRIRAM.NS's P/E ratio is 20.33. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to DCMSHRIRAM.NS's ROE of +0.12%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to DCMSHRIRAM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check DCMSHRIRAM.NS's competition here
ADVENZYMES.BO vs AARTIIND.BO Comparison May 2026
ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADVENZYMES.BO stands at 42B. In comparison, AARTIIND.BO has a market cap of 172.7B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹376.50, while AARTIIND.BO trades at ₹482.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADVENZYMES.BO currently has a P/E ratio of 24.94, whereas AARTIIND.BO's P/E ratio is 45.75. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to AARTIIND.BO's ROE of +0.07%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to AARTIIND.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check AARTIIND.BO's competition here
ADVENZYMES.BO vs AARTIIND.NS Comparison May 2026
ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADVENZYMES.BO stands at 42B. In comparison, AARTIIND.NS has a market cap of 172.7B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹376.50, while AARTIIND.NS trades at ₹482.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADVENZYMES.BO currently has a P/E ratio of 24.94, whereas AARTIIND.NS's P/E ratio is 41.27. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to AARTIIND.NS's ROE of +0.07%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to AARTIIND.NS. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check AARTIIND.NS's competition here
ADVENZYMES.BO vs ANURAS.NS Comparison May 2026
ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADVENZYMES.BO stands at 42B. In comparison, ANURAS.NS has a market cap of 155.5B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹376.50, while ANURAS.NS trades at ₹1,371.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADVENZYMES.BO currently has a P/E ratio of 24.94, whereas ANURAS.NS's P/E ratio is 88.94. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to ANURAS.NS's ROE of +0.06%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to ANURAS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check ANURAS.NS's competition here
ADVENZYMES.BO vs ANURAS.BO Comparison May 2026
ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADVENZYMES.BO stands at 42B. In comparison, ANURAS.BO has a market cap of 155.3B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹376.50, while ANURAS.BO trades at ₹1,371.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADVENZYMES.BO currently has a P/E ratio of 24.94, whereas ANURAS.BO's P/E ratio is 88.22. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to ANURAS.BO's ROE of +0.06%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to ANURAS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check ANURAS.BO's competition here
ADVENZYMES.BO vs BASF.NS Comparison May 2026
ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADVENZYMES.BO stands at 42B. In comparison, BASF.NS has a market cap of 151B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹376.50, while BASF.NS trades at ₹3,515.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADVENZYMES.BO currently has a P/E ratio of 24.94, whereas BASF.NS's P/E ratio is 36.34. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to BASF.NS's ROE of +0.11%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to BASF.NS. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check BASF.NS's competition here
ADVENZYMES.BO vs BASF.BO Comparison May 2026
ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADVENZYMES.BO stands at 42B. In comparison, BASF.BO has a market cap of 151B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹376.50, while BASF.BO trades at ₹3,515.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADVENZYMES.BO currently has a P/E ratio of 24.94, whereas BASF.BO's P/E ratio is 40.19. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to BASF.BO's ROE of +0.11%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to BASF.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check BASF.BO's competition here
ADVENZYMES.BO vs FINEORG.BO Comparison May 2026
ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADVENZYMES.BO stands at 42B. In comparison, FINEORG.BO has a market cap of 141.2B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹376.50, while FINEORG.BO trades at ₹4,556.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADVENZYMES.BO currently has a P/E ratio of 24.94, whereas FINEORG.BO's P/E ratio is 33.86. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to FINEORG.BO's ROE of +0.17%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to FINEORG.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check FINEORG.BO's competition here
ADVENZYMES.BO vs FINEORG.NS Comparison May 2026
ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADVENZYMES.BO stands at 42B. In comparison, FINEORG.NS has a market cap of 141.2B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹376.50, while FINEORG.NS trades at ₹4,557.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADVENZYMES.BO currently has a P/E ratio of 24.94, whereas FINEORG.NS's P/E ratio is 33.76. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to FINEORG.NS's ROE of +0.17%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to FINEORG.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check FINEORG.NS's competition here
ADVENZYMES.BO vs AETHER.BO Comparison May 2026
ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADVENZYMES.BO stands at 42B. In comparison, AETHER.BO has a market cap of 139.7B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹376.50, while AETHER.BO trades at ₹1,076.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADVENZYMES.BO currently has a P/E ratio of 24.94, whereas AETHER.BO's P/E ratio is 63.55. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to AETHER.BO's ROE of +0.10%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to AETHER.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check AETHER.BO's competition here
ADVENZYMES.BO vs AETHER.NS Comparison May 2026
ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADVENZYMES.BO stands at 42B. In comparison, AETHER.NS has a market cap of 139.5B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹376.50, while AETHER.NS trades at ₹1,074.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADVENZYMES.BO currently has a P/E ratio of 24.94, whereas AETHER.NS's P/E ratio is 63.45. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to AETHER.NS's ROE of +0.10%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to AETHER.NS. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check AETHER.NS's competition here
ADVENZYMES.BO vs VINATIORGA.BO Comparison May 2026
ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADVENZYMES.BO stands at 42B. In comparison, VINATIORGA.BO has a market cap of 136.8B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹376.50, while VINATIORGA.BO trades at ₹1,337.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADVENZYMES.BO currently has a P/E ratio of 24.94, whereas VINATIORGA.BO's P/E ratio is 30.87. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to VINATIORGA.BO's ROE of +0.15%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to VINATIORGA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check VINATIORGA.BO's competition here
ADVENZYMES.BO vs VINATIORGA.NS Comparison May 2026
ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADVENZYMES.BO stands at 42B. In comparison, VINATIORGA.NS has a market cap of 136.7B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹376.50, while VINATIORGA.NS trades at ₹1,339.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADVENZYMES.BO currently has a P/E ratio of 24.94, whereas VINATIORGA.NS's P/E ratio is 30.80. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to VINATIORGA.NS's ROE of +0.15%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to VINATIORGA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check VINATIORGA.NS's competition here
ADVENZYMES.BO vs AKZOINDIA.NS Comparison May 2026
ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADVENZYMES.BO stands at 42B. In comparison, AKZOINDIA.NS has a market cap of 136B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹376.50, while AKZOINDIA.NS trades at ₹2,986.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADVENZYMES.BO currently has a P/E ratio of 24.94, whereas AKZOINDIA.NS's P/E ratio is 6.95. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to AKZOINDIA.NS's ROE of +1.07%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to AKZOINDIA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check AKZOINDIA.NS's competition here
ADVENZYMES.BO vs AKZOINDIA.BO Comparison May 2026
ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADVENZYMES.BO stands at 42B. In comparison, AKZOINDIA.BO has a market cap of 136B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹376.50, while AKZOINDIA.BO trades at ₹2,985.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADVENZYMES.BO currently has a P/E ratio of 24.94, whereas AKZOINDIA.BO's P/E ratio is 6.95. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to AKZOINDIA.BO's ROE of +1.07%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to AKZOINDIA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check AKZOINDIA.BO's competition here
ADVENZYMES.BO vs PRIVISCL.BO Comparison May 2026
ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADVENZYMES.BO stands at 42B. In comparison, PRIVISCL.BO has a market cap of 129.7B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹376.50, while PRIVISCL.BO trades at ₹3,296.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADVENZYMES.BO currently has a P/E ratio of 24.94, whereas PRIVISCL.BO's P/E ratio is 39.54. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to PRIVISCL.BO's ROE of +0.27%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to PRIVISCL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check PRIVISCL.BO's competition here
ADVENZYMES.BO vs PRIVISCL.NS Comparison May 2026
ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADVENZYMES.BO stands at 42B. In comparison, PRIVISCL.NS has a market cap of 129.6B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹376.50, while PRIVISCL.NS trades at ₹3,300.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADVENZYMES.BO currently has a P/E ratio of 24.94, whereas PRIVISCL.NS's P/E ratio is 39.52. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to PRIVISCL.NS's ROE of +0.27%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to PRIVISCL.NS. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check PRIVISCL.NS's competition here
ADVENZYMES.BO vs GRWRHITECH.BO Comparison May 2026
ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADVENZYMES.BO stands at 42B. In comparison, GRWRHITECH.BO has a market cap of 124.4B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹376.50, while GRWRHITECH.BO trades at ₹5,590.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADVENZYMES.BO currently has a P/E ratio of 24.94, whereas GRWRHITECH.BO's P/E ratio is 36.75. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to GRWRHITECH.BO's ROE of +0.14%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to GRWRHITECH.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check GRWRHITECH.BO's competition here
ADVENZYMES.BO vs GRWRHITECH.NS Comparison May 2026
ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADVENZYMES.BO stands at 42B. In comparison, GRWRHITECH.NS has a market cap of 124.4B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹376.50, while GRWRHITECH.NS trades at ₹5,587.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADVENZYMES.BO currently has a P/E ratio of 24.94, whereas GRWRHITECH.NS's P/E ratio is 36.82. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to GRWRHITECH.NS's ROE of +0.14%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to GRWRHITECH.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check GRWRHITECH.NS's competition here
ADVENZYMES.BO vs PCBL.NS Comparison May 2026
ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADVENZYMES.BO stands at 42B. In comparison, PCBL.NS has a market cap of 115.4B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹376.50, while PCBL.NS trades at ₹294.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADVENZYMES.BO currently has a P/E ratio of 24.94, whereas PCBL.NS's P/E ratio is 43.37. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to PCBL.NS's ROE of +0.05%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to PCBL.NS. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check PCBL.NS's competition here
ADVENZYMES.BO vs PCBL.BO Comparison May 2026
ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADVENZYMES.BO stands at 42B. In comparison, PCBL.BO has a market cap of 115.3B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹376.50, while PCBL.BO trades at ₹294.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADVENZYMES.BO currently has a P/E ratio of 24.94, whereas PCBL.BO's P/E ratio is 43.36. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to PCBL.BO's ROE of +0.05%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to PCBL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check PCBL.BO's competition here
ADVENZYMES.BO vs JUBLINGREA.NS Comparison May 2026
ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADVENZYMES.BO stands at 42B. In comparison, JUBLINGREA.NS has a market cap of 114.8B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹376.50, while JUBLINGREA.NS trades at ₹731.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADVENZYMES.BO currently has a P/E ratio of 24.94, whereas JUBLINGREA.NS's P/E ratio is 43.42. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to JUBLINGREA.NS's ROE of +0.09%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to JUBLINGREA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check JUBLINGREA.NS's competition here
ADVENZYMES.BO vs JUBLINGREA.BO Comparison May 2026
ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADVENZYMES.BO stands at 42B. In comparison, JUBLINGREA.BO has a market cap of 114.8B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹376.50, while JUBLINGREA.BO trades at ₹731.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADVENZYMES.BO currently has a P/E ratio of 24.94, whereas JUBLINGREA.BO's P/E ratio is 43.39. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to JUBLINGREA.BO's ROE of +0.09%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to JUBLINGREA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check JUBLINGREA.BO's competition here
ADVENZYMES.BO vs AMIORG.NS Comparison May 2026
ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADVENZYMES.BO stands at 42B. In comparison, AMIORG.NS has a market cap of 96.3B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹376.50, while AMIORG.NS trades at ₹1,176.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADVENZYMES.BO currently has a P/E ratio of 24.94, whereas AMIORG.NS's P/E ratio is 119.06. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to AMIORG.NS's ROE of +0.12%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to AMIORG.NS. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check AMIORG.NS's competition here
ADVENZYMES.BO vs AMIORG.BO Comparison May 2026
ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADVENZYMES.BO stands at 42B. In comparison, AMIORG.BO has a market cap of 96.3B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹376.50, while AMIORG.BO trades at ₹1,176.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADVENZYMES.BO currently has a P/E ratio of 24.94, whereas AMIORG.BO's P/E ratio is 118.95. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to AMIORG.BO's ROE of +0.12%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to AMIORG.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check AMIORG.BO's competition here
ADVENZYMES.BO vs ALKYLAMINE.NS Comparison May 2026
ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADVENZYMES.BO stands at 42B. In comparison, ALKYLAMINE.NS has a market cap of 88B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹376.50, while ALKYLAMINE.NS trades at ₹1,745.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADVENZYMES.BO currently has a P/E ratio of 24.94, whereas ALKYLAMINE.NS's P/E ratio is 48.93. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to ALKYLAMINE.NS's ROE of +0.12%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to ALKYLAMINE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check ALKYLAMINE.NS's competition here
ADVENZYMES.BO vs ALKYLAMINE.BO Comparison May 2026
ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADVENZYMES.BO stands at 42B. In comparison, ALKYLAMINE.BO has a market cap of 87.9B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹376.50, while ALKYLAMINE.BO trades at ₹1,748.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADVENZYMES.BO currently has a P/E ratio of 24.94, whereas ALKYLAMINE.BO's P/E ratio is 48.80. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to ALKYLAMINE.BO's ROE of +0.12%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to ALKYLAMINE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check ALKYLAMINE.BO's competition here
ADVENZYMES.BO vs CLEAN.BO Comparison May 2026
ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADVENZYMES.BO stands at 42B. In comparison, CLEAN.BO has a market cap of 80.6B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹376.50, while CLEAN.BO trades at ₹746.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADVENZYMES.BO currently has a P/E ratio of 24.94, whereas CLEAN.BO's P/E ratio is 35.05. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to CLEAN.BO's ROE of +0.16%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to CLEAN.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check CLEAN.BO's competition here
ADVENZYMES.BO vs CLEAN.NS Comparison May 2026
ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADVENZYMES.BO stands at 42B. In comparison, CLEAN.NS has a market cap of 80.4B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹376.50, while CLEAN.NS trades at ₹745.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADVENZYMES.BO currently has a P/E ratio of 24.94, whereas CLEAN.NS's P/E ratio is 35.05. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to CLEAN.NS's ROE of +0.16%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to CLEAN.NS. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check CLEAN.NS's competition here
ADVENZYMES.BO vs SUDARSCHEM.BO Comparison May 2026
ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADVENZYMES.BO stands at 42B. In comparison, SUDARSCHEM.BO has a market cap of 79.8B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹376.50, while SUDARSCHEM.BO trades at ₹1,044.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADVENZYMES.BO currently has a P/E ratio of 24.94, whereas SUDARSCHEM.BO's P/E ratio is 150.21. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to SUDARSCHEM.BO's ROE of -0.02%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to SUDARSCHEM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check SUDARSCHEM.BO's competition here
ADVENZYMES.BO vs SUDARSCHEM.NS Comparison May 2026
ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADVENZYMES.BO stands at 42B. In comparison, SUDARSCHEM.NS has a market cap of 79.6B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹376.50, while SUDARSCHEM.NS trades at ₹1,043.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADVENZYMES.BO currently has a P/E ratio of 24.94, whereas SUDARSCHEM.NS's P/E ratio is -128.88. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to SUDARSCHEM.NS's ROE of -0.02%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to SUDARSCHEM.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check SUDARSCHEM.NS's competition here
ADVENZYMES.BO vs KINGFA.BO Comparison May 2026
ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADVENZYMES.BO stands at 42B. In comparison, KINGFA.BO has a market cap of 69.8B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹376.50, while KINGFA.BO trades at ₹5,240.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADVENZYMES.BO currently has a P/E ratio of 24.94, whereas KINGFA.BO's P/E ratio is 40.31. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to KINGFA.BO's ROE of +0.20%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to KINGFA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check KINGFA.BO's competition here
ADVENZYMES.BO vs KINGFA.NS Comparison May 2026
ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADVENZYMES.BO stands at 42B. In comparison, KINGFA.NS has a market cap of 69.6B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹376.50, while KINGFA.NS trades at ₹5,271.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADVENZYMES.BO currently has a P/E ratio of 24.94, whereas KINGFA.NS's P/E ratio is 40.28. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to KINGFA.NS's ROE of +0.20%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to KINGFA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check KINGFA.NS's competition here
ADVENZYMES.BO vs GALAXYSURF.NS Comparison May 2026
ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADVENZYMES.BO stands at 42B. In comparison, GALAXYSURF.NS has a market cap of 64.6B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹376.50, while GALAXYSURF.NS trades at ₹1,840.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADVENZYMES.BO currently has a P/E ratio of 24.94, whereas GALAXYSURF.NS's P/E ratio is 24.16. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to GALAXYSURF.NS's ROE of +0.11%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to GALAXYSURF.NS. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check GALAXYSURF.NS's competition here
ADVENZYMES.BO vs GALAXYSURF.BO Comparison May 2026
ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADVENZYMES.BO stands at 42B. In comparison, GALAXYSURF.BO has a market cap of 64.5B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹376.50, while GALAXYSURF.BO trades at ₹1,840.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADVENZYMES.BO currently has a P/E ratio of 24.94, whereas GALAXYSURF.BO's P/E ratio is 24.16. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to GALAXYSURF.BO's ROE of +0.11%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to GALAXYSURF.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check GALAXYSURF.BO's competition here
ADVENZYMES.BO vs BALAMINES.NS Comparison May 2026
ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADVENZYMES.BO stands at 42B. In comparison, BALAMINES.NS has a market cap of 59.1B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹376.50, while BALAMINES.NS trades at ₹1,920.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADVENZYMES.BO currently has a P/E ratio of 24.94, whereas BALAMINES.NS's P/E ratio is 35.31. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to BALAMINES.NS's ROE of +0.09%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to BALAMINES.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check BALAMINES.NS's competition here
ADVENZYMES.BO vs BALAMINES.BO Comparison May 2026
ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADVENZYMES.BO stands at 42B. In comparison, BALAMINES.BO has a market cap of 59B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹376.50, while BALAMINES.BO trades at ₹1,920.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADVENZYMES.BO currently has a P/E ratio of 24.94, whereas BALAMINES.BO's P/E ratio is 35.35. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to BALAMINES.BO's ROE of +0.09%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to BALAMINES.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check BALAMINES.BO's competition here
ADVENZYMES.BO vs INDIGOPNTS.NS Comparison May 2026
ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADVENZYMES.BO stands at 42B. In comparison, INDIGOPNTS.NS has a market cap of 47.8B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹376.50, while INDIGOPNTS.NS trades at ₹995.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADVENZYMES.BO currently has a P/E ratio of 24.94, whereas INDIGOPNTS.NS's P/E ratio is 33.29. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to INDIGOPNTS.NS's ROE of +0.14%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to INDIGOPNTS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check INDIGOPNTS.NS's competition here
ADVENZYMES.BO vs INDIGOPNTS.BO Comparison May 2026
ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADVENZYMES.BO stands at 42B. In comparison, INDIGOPNTS.BO has a market cap of 47.8B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹376.50, while INDIGOPNTS.BO trades at ₹995.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADVENZYMES.BO currently has a P/E ratio of 24.94, whereas INDIGOPNTS.BO's P/E ratio is 33.24. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to INDIGOPNTS.BO's ROE of +0.14%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to INDIGOPNTS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check INDIGOPNTS.BO's competition here
ADVENZYMES.BO vs POCL.BO Comparison May 2026
ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADVENZYMES.BO stands at 42B. In comparison, POCL.BO has a market cap of 45.3B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹376.50, while POCL.BO trades at ₹1,505.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADVENZYMES.BO currently has a P/E ratio of 24.94, whereas POCL.BO's P/E ratio is 39.70. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to POCL.BO's ROE of +0.20%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to POCL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check POCL.BO's competition here
ADVENZYMES.BO vs POCL.NS Comparison May 2026
ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADVENZYMES.BO stands at 42B. In comparison, POCL.NS has a market cap of 45.2B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹376.50, while POCL.NS trades at ₹1,507.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADVENZYMES.BO currently has a P/E ratio of 24.94, whereas POCL.NS's P/E ratio is 39.66. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to POCL.NS's ROE of +0.20%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to POCL.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check POCL.NS's competition here
ADVENZYMES.BO vs GULFOILLUB.NS Comparison May 2026
ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADVENZYMES.BO stands at 42B. In comparison, GULFOILLUB.NS has a market cap of 44.6B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹376.50, while GULFOILLUB.NS trades at ₹924.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADVENZYMES.BO currently has a P/E ratio of 24.94, whereas GULFOILLUB.NS's P/E ratio is 12.84. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to GULFOILLUB.NS's ROE of +0.23%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to GULFOILLUB.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check GULFOILLUB.NS's competition here
ADVENZYMES.BO vs GULFOILLUB.BO Comparison May 2026
ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADVENZYMES.BO stands at 42B. In comparison, GULFOILLUB.BO has a market cap of 44.6B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹376.50, while GULFOILLUB.BO trades at ₹923.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADVENZYMES.BO currently has a P/E ratio of 24.94, whereas GULFOILLUB.BO's P/E ratio is 12.83. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to GULFOILLUB.BO's ROE of +0.23%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to GULFOILLUB.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check GULFOILLUB.BO's competition here
ADVENZYMES.BO vs NEOGEN.BO Comparison May 2026
ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADVENZYMES.BO stands at 42B. In comparison, NEOGEN.BO has a market cap of 44.5B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹376.50, while NEOGEN.BO trades at ₹1,755.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADVENZYMES.BO currently has a P/E ratio of 24.94, whereas NEOGEN.BO's P/E ratio is 227.87. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to NEOGEN.BO's ROE of +0.04%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to NEOGEN.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check NEOGEN.BO's competition here
ADVENZYMES.BO vs NEOGEN.NS Comparison May 2026
ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADVENZYMES.BO stands at 42B. In comparison, NEOGEN.NS has a market cap of 44.5B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹376.50, while NEOGEN.NS trades at ₹1,754.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADVENZYMES.BO currently has a P/E ratio of 24.94, whereas NEOGEN.NS's P/E ratio is 226.15. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to NEOGEN.NS's ROE of +0.04%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to NEOGEN.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check NEOGEN.NS's competition here
ADVENZYMES.BO vs RESPONIND.NS Comparison May 2026
ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADVENZYMES.BO stands at 42B. In comparison, RESPONIND.NS has a market cap of 44.2B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹376.50, while RESPONIND.NS trades at ₹174.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADVENZYMES.BO currently has a P/E ratio of 24.94, whereas RESPONIND.NS's P/E ratio is 24.57. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to RESPONIND.NS's ROE of +0.13%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to RESPONIND.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check RESPONIND.NS's competition here
ADVENZYMES.BO vs RESPONIND.BO Comparison May 2026
ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADVENZYMES.BO stands at 42B. In comparison, RESPONIND.BO has a market cap of 44.2B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹376.50, while RESPONIND.BO trades at ₹175.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADVENZYMES.BO currently has a P/E ratio of 24.94, whereas RESPONIND.BO's P/E ratio is 24.50. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to RESPONIND.BO's ROE of +0.13%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to RESPONIND.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check RESPONIND.BO's competition here
ADVENZYMES.BO vs LXCHEM.NS Comparison May 2026
ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADVENZYMES.BO stands at 42B. In comparison, LXCHEM.NS has a market cap of 42.1B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹376.50, while LXCHEM.NS trades at ₹154.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADVENZYMES.BO currently has a P/E ratio of 24.94, whereas LXCHEM.NS's P/E ratio is 52.71. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to LXCHEM.NS's ROE of +0.04%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to LXCHEM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check LXCHEM.NS's competition here
ADVENZYMES.BO vs LXCHEM.BO Comparison May 2026
ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADVENZYMES.BO stands at 42B. In comparison, LXCHEM.BO has a market cap of 42.1B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹376.50, while LXCHEM.BO trades at ₹154.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADVENZYMES.BO currently has a P/E ratio of 24.94, whereas LXCHEM.BO's P/E ratio is 52.67. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to LXCHEM.BO's ROE of +0.04%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to LXCHEM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check LXCHEM.BO's competition here
ADVENZYMES.BO vs TANFACIND.BO Comparison May 2026
ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADVENZYMES.BO stands at 42B. In comparison, TANFACIND.BO has a market cap of 42B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹376.50, while TANFACIND.BO trades at ₹2,037.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADVENZYMES.BO currently has a P/E ratio of 24.94, whereas TANFACIND.BO's P/E ratio is 59.82. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to TANFACIND.BO's ROE of +0.22%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to TANFACIND.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check TANFACIND.BO's competition here
ADVENZYMES.BO vs ADVENZYMES.NS Comparison May 2026
ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADVENZYMES.BO stands at 42B. In comparison, ADVENZYMES.NS has a market cap of 42B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹376.50, while ADVENZYMES.NS trades at ₹376.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADVENZYMES.BO currently has a P/E ratio of 24.94, whereas ADVENZYMES.NS's P/E ratio is 24.91. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to ADVENZYMES.NS's ROE of +0.11%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to ADVENZYMES.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check ADVENZYMES.NS's competition here
ADVENZYMES.BO vs VISHNU.NS Comparison May 2026
ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADVENZYMES.BO stands at 42B. In comparison, VISHNU.NS has a market cap of 40.3B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹376.50, while VISHNU.NS trades at ₹603.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADVENZYMES.BO currently has a P/E ratio of 24.94, whereas VISHNU.NS's P/E ratio is 29.16. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to VISHNU.NS's ROE of +0.15%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to VISHNU.NS. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check VISHNU.NS's competition here
ADVENZYMES.BO vs VISHNU.BO Comparison May 2026
ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADVENZYMES.BO stands at 42B. In comparison, VISHNU.BO has a market cap of 40.3B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹376.50, while VISHNU.BO trades at ₹603.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADVENZYMES.BO currently has a P/E ratio of 24.94, whereas VISHNU.BO's P/E ratio is 29.20. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to VISHNU.BO's ROE of +0.15%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to VISHNU.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check VISHNU.BO's competition here
ADVENZYMES.BO vs PREMEXPLN.BO Comparison May 2026
ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADVENZYMES.BO stands at 42B. In comparison, PREMEXPLN.BO has a market cap of 32B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹376.50, while PREMEXPLN.BO trades at ₹714.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADVENZYMES.BO currently has a P/E ratio of 24.94, whereas PREMEXPLN.BO's P/E ratio is 74.36. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to PREMEXPLN.BO's ROE of +0.17%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to PREMEXPLN.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check PREMEXPLN.BO's competition here
ADVENZYMES.BO vs PREMEXPLN.NS Comparison May 2026
ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADVENZYMES.BO stands at 42B. In comparison, PREMEXPLN.NS has a market cap of 32B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹376.50, while PREMEXPLN.NS trades at ₹714.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADVENZYMES.BO currently has a P/E ratio of 24.94, whereas PREMEXPLN.NS's P/E ratio is 74.44. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to PREMEXPLN.NS's ROE of +0.17%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to PREMEXPLN.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check PREMEXPLN.NS's competition here
ADVENZYMES.BO vs GRAUWEIL.BO Comparison May 2026
ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADVENZYMES.BO stands at 42B. In comparison, GRAUWEIL.BO has a market cap of 30.9B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹376.50, while GRAUWEIL.BO trades at ₹68.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADVENZYMES.BO currently has a P/E ratio of 24.94, whereas GRAUWEIL.BO's P/E ratio is 22.02. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to GRAUWEIL.BO's ROE of +0.15%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to GRAUWEIL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check GRAUWEIL.BO's competition here
ADVENZYMES.BO vs GRAUWEIL.NS Comparison May 2026
ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADVENZYMES.BO stands at 42B. In comparison, GRAUWEIL.NS has a market cap of 30.9B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹376.50, while GRAUWEIL.NS trades at ₹68.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADVENZYMES.BO currently has a P/E ratio of 24.94, whereas GRAUWEIL.NS's P/E ratio is 22.01. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to GRAUWEIL.NS's ROE of +0.15%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to GRAUWEIL.NS. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check GRAUWEIL.NS's competition here
ADVENZYMES.BO vs JINDALPOLY.NS Comparison May 2026
ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADVENZYMES.BO stands at 42B. In comparison, JINDALPOLY.NS has a market cap of 30.9B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹376.50, while JINDALPOLY.NS trades at ₹706.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADVENZYMES.BO currently has a P/E ratio of 24.94, whereas JINDALPOLY.NS's P/E ratio is -14.53. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to JINDALPOLY.NS's ROE of -0.06%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to JINDALPOLY.NS. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check JINDALPOLY.NS's competition here
ADVENZYMES.BO vs JINDALPOLY.BO Comparison May 2026
ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADVENZYMES.BO stands at 42B. In comparison, JINDALPOLY.BO has a market cap of 30.6B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹376.50, while JINDALPOLY.BO trades at ₹703.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADVENZYMES.BO currently has a P/E ratio of 24.94, whereas JINDALPOLY.BO's P/E ratio is -23.61. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to JINDALPOLY.BO's ROE of -0.06%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to JINDALPOLY.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check JINDALPOLY.BO's competition here
ADVENZYMES.BO vs POLYPLEX.BO Comparison May 2026
ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADVENZYMES.BO stands at 42B. In comparison, POLYPLEX.BO has a market cap of 30.2B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹376.50, while POLYPLEX.BO trades at ₹913.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADVENZYMES.BO currently has a P/E ratio of 24.94, whereas POLYPLEX.BO's P/E ratio is 99.36. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to POLYPLEX.BO's ROE of +0.01%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to POLYPLEX.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check POLYPLEX.BO's competition here
ADVENZYMES.BO vs POLYPLEX.NS Comparison May 2026
ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADVENZYMES.BO stands at 42B. In comparison, POLYPLEX.NS has a market cap of 30.2B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹376.50, while POLYPLEX.NS trades at ₹913.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADVENZYMES.BO currently has a P/E ratio of 24.94, whereas POLYPLEX.NS's P/E ratio is 99.53. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to POLYPLEX.NS's ROE of +0.01%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to POLYPLEX.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check POLYPLEX.NS's competition here
ADVENZYMES.BO vs SOTL.NS Comparison May 2026
ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADVENZYMES.BO stands at 42B. In comparison, SOTL.NS has a market cap of 29.2B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹376.50, while SOTL.NS trades at ₹424.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADVENZYMES.BO currently has a P/E ratio of 24.94, whereas SOTL.NS's P/E ratio is 16.05. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to SOTL.NS's ROE of +0.11%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to SOTL.NS. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check SOTL.NS's competition here
ADVENZYMES.BO vs ROSSARI.BO Comparison May 2026
ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADVENZYMES.BO stands at 42B. In comparison, ROSSARI.BO has a market cap of 29.2B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹376.50, while ROSSARI.BO trades at ₹539.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADVENZYMES.BO currently has a P/E ratio of 24.94, whereas ROSSARI.BO's P/E ratio is 19.56. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to ROSSARI.BO's ROE of +0.12%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to ROSSARI.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check ROSSARI.BO's competition here
ADVENZYMES.BO vs SOTL.BO Comparison May 2026
ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADVENZYMES.BO stands at 42B. In comparison, SOTL.BO has a market cap of 29.1B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹376.50, while SOTL.BO trades at ₹424.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADVENZYMES.BO currently has a P/E ratio of 24.94, whereas SOTL.BO's P/E ratio is 16.00. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to SOTL.BO's ROE of +0.11%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to SOTL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check SOTL.BO's competition here
ADVENZYMES.BO vs ROSSARI.NS Comparison May 2026
ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADVENZYMES.BO stands at 42B. In comparison, ROSSARI.NS has a market cap of 29B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹376.50, while ROSSARI.NS trades at ₹538.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADVENZYMES.BO currently has a P/E ratio of 24.94, whereas ROSSARI.NS's P/E ratio is 19.45. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to ROSSARI.NS's ROE of +0.12%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to ROSSARI.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check ROSSARI.NS's competition here
ADVENZYMES.BO vs NOCIL.NS Comparison May 2026
ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADVENZYMES.BO stands at 42B. In comparison, NOCIL.NS has a market cap of 28.1B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹376.50, while NOCIL.NS trades at ₹165.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADVENZYMES.BO currently has a P/E ratio of 24.94, whereas NOCIL.NS's P/E ratio is 50.78. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to NOCIL.NS's ROE of +0.03%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to NOCIL.NS. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check NOCIL.NS's competition here
ADVENZYMES.BO vs NOCIL.BO Comparison May 2026
ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADVENZYMES.BO stands at 42B. In comparison, NOCIL.BO has a market cap of 28.1B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹376.50, while NOCIL.BO trades at ₹166.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADVENZYMES.BO currently has a P/E ratio of 24.94, whereas NOCIL.BO's P/E ratio is 44.56. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to NOCIL.BO's ROE of +0.03%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to NOCIL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check NOCIL.BO's competition here
ADVENZYMES.BO vs TATVA.BO Comparison May 2026
ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADVENZYMES.BO stands at 42B. In comparison, TATVA.BO has a market cap of 27.8B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹376.50, while TATVA.BO trades at ₹1,182.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADVENZYMES.BO currently has a P/E ratio of 24.94, whereas TATVA.BO's P/E ratio is 84.93. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to TATVA.BO's ROE of +0.06%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to TATVA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check TATVA.BO's competition here
ADVENZYMES.BO vs TATVA.NS Comparison May 2026
ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADVENZYMES.BO stands at 42B. In comparison, TATVA.NS has a market cap of 27.8B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹376.50, while TATVA.NS trades at ₹1,182.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADVENZYMES.BO currently has a P/E ratio of 24.94, whereas TATVA.NS's P/E ratio is 84.64. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to TATVA.NS's ROE of +0.06%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to TATVA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check TATVA.NS's competition here
ADVENZYMES.BO vs JUBLCPL.NS Comparison May 2026
ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADVENZYMES.BO stands at 42B. In comparison, JUBLCPL.NS has a market cap of 27.7B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹376.50, while JUBLCPL.NS trades at ₹1,830.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADVENZYMES.BO currently has a P/E ratio of 24.94, whereas JUBLCPL.NS's P/E ratio is 22.81. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to JUBLCPL.NS's ROE of +0.33%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to JUBLCPL.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check JUBLCPL.NS's competition here
ADVENZYMES.BO vs JUBLCPL.BO Comparison May 2026
ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADVENZYMES.BO stands at 42B. In comparison, JUBLCPL.BO has a market cap of 27.7B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹376.50, while JUBLCPL.BO trades at ₹1,825.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADVENZYMES.BO currently has a P/E ratio of 24.94, whereas JUBLCPL.BO's P/E ratio is 22.84. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to JUBLCPL.BO's ROE of +0.13%. Regarding short-term risk, ADVENZYMES.BO is more volatile compared to JUBLCPL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check JUBLCPL.BO's competition here
ADVENZYMES.BO vs XPROINDIA.NS Comparison May 2026
ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADVENZYMES.BO stands at 42B. In comparison, XPROINDIA.NS has a market cap of 27B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹376.50, while XPROINDIA.NS trades at ₹1,116.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADVENZYMES.BO currently has a P/E ratio of 24.94, whereas XPROINDIA.NS's P/E ratio is 204.77. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to XPROINDIA.NS's ROE of +0.02%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to XPROINDIA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check XPROINDIA.NS's competition here
ADVENZYMES.BO vs XPROINDIA.BO Comparison May 2026
ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADVENZYMES.BO stands at 42B. In comparison, XPROINDIA.BO has a market cap of 26.9B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹376.50, while XPROINDIA.BO trades at ₹1,119.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADVENZYMES.BO currently has a P/E ratio of 24.94, whereas XPROINDIA.BO's P/E ratio is 204.05. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to XPROINDIA.BO's ROE of +0.02%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to XPROINDIA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check XPROINDIA.BO's competition here
ADVENZYMES.BO vs APCOTEXIND.NS Comparison May 2026
ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADVENZYMES.BO stands at 42B. In comparison, APCOTEXIND.NS has a market cap of 25.8B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹376.50, while APCOTEXIND.NS trades at ₹494.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADVENZYMES.BO currently has a P/E ratio of 24.94, whereas APCOTEXIND.NS's P/E ratio is 25.42. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to APCOTEXIND.NS's ROE of +0.18%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to APCOTEXIND.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check APCOTEXIND.NS's competition here
ADVENZYMES.BO vs APCOTEXIND.BO Comparison May 2026
ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADVENZYMES.BO stands at 42B. In comparison, APCOTEXIND.BO has a market cap of 25.7B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹376.50, while APCOTEXIND.BO trades at ₹494.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADVENZYMES.BO currently has a P/E ratio of 24.94, whereas APCOTEXIND.BO's P/E ratio is 30.82. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to APCOTEXIND.BO's ROE of +0.18%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to APCOTEXIND.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check APCOTEXIND.BO's competition here
ADVENZYMES.BO vs JUBLINDS.NS Comparison May 2026
ADVENZYMES.BO plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADVENZYMES.BO stands at 42B. In comparison, JUBLINDS.NS has a market cap of 25.6B. Regarding current trading prices, ADVENZYMES.BO is priced at ₹376.50, while JUBLINDS.NS trades at ₹1,633.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADVENZYMES.BO currently has a P/E ratio of 24.94, whereas JUBLINDS.NS's P/E ratio is 72.49. In terms of profitability, ADVENZYMES.BO's ROE is +0.11%, compared to JUBLINDS.NS's ROE of +0.13%. Regarding short-term risk, ADVENZYMES.BO is less volatile compared to JUBLINDS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ADVENZYMES.BO.Check JUBLINDS.NS's competition here